Improving Patients' Adherence to Their Chronic Treatments by Implementing a Simple, Standardized and Redundant Message Delivered by Healthcare Professionals.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

The primary objective in this study is to achieve a 15% 6-month improvement in therapeutic adherence among patients with chronic pathologies, thanks to a simple, standardized and redundant message delivered by healthcare professionals during consultations/interviews Trained healthcare professionals deliver a simple, standardized and redundant 3-point message to patients, based on the levers of action concerning therapeutic adherence. This message is delivered with the aim of modifying the patient's behavior with regard to treatment intake.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients (age ≥ 18 years)

Affiliated to the French social security system

Followed in hospital for a chronic pathology within a formalized care pathway

Having signed a consent form to participate in the study.

Disqualifiers

Patients included in the control period.

Patients under guardianship.

Pregnant or breast-feeding patients.

Patients taking part in research on compliance

Trial design

Design model

Sequential

Treatments tested in this trial

  • Trained healthcare professionals deliver a simple, standardized and redundant 3-point message to patients, based on the levers of action for therapeutic adherence.

    Other intervention

    This message is delivered with the aim of modifying the patient's behavior with regard to treatment intake. The research does not anticipate any change in the patient's medical prescriptions.

Treatment groups

1,210 Participants
are divided into 2 treatment groups
Group A: Intervention periodExperimental treatment 1 intervention
Group B: Control periodNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Improvement in therapeutic adherence

The medication possession ratio (MPR), calculated as the ratio between the sum of treatment days delivered over the period of interest x 100, expressed as a %. In the literature, an MPR ≥ 80% corresponds to good therapeutic adherence.

Time frame
6 months

Secondary outcomes

1

Improvement in therapeutic adherence

The medication possession ratio (MPR), calculated as the ratio between the sum of treatment days delivered over the period of interest x 100, expressed as a %.

Time frame
12 months
2

Predictive factors of improved adherence factors predictive of therapeutic adherence

Identification of predictive factors for improving adherence assessed by the Freedom patient self-questionnaire and known factors.

Time frame
6 months
3

Improvement in therapeutic adherence estimated

patient adherence self-questionnaire, taking into account what the patient says between M0 and M3, M3 and M6; and between M0 and M12, M6 and M12 (11 questions formulated using a 5-point Likert scale), which classifies patients' therapeutic adherence into 3 classes: "low therapeutic adherence / average / high". Improvement in adherence will be assessed by changing the adherence category.

Time frame
12 months
4

Costs of care according to periods (control vs. intervention)

The number of consultations (general practitioner, specialist, nurse), hospital admissions (day and conventional), emergency room visits, and the number and duration of days off work will be collected prospectively via a questionnaire on the evaluation of healthcare use given to the patient at M0, M3, M6 and M12. Costs will then be evaluated using the official tariffs for each procedure or hospitalization. Treatment costs will be evaluated on the basis of data from copies of prescriptions collected by pharmacists at each center.

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assistance Publique - Hôpitaux de Paris

Lead sponsor

Ministry of Health, France

Collaborator